----item----
version: 1
id: {2C7D308A-A5A3-4D62-BAAD-170AFBD19521}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/08/14/PharmAsia News Business Bulletin
parent: {F1BDB59F-EC79-4308-B3FA-AD67FD3F4F4E}
name: PharmAsia News Business Bulletin
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 3bb79af2-36e1-4a13-bf78-e8feaeea632f

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 5985

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>&rsquo;s sister publication <i>PharmAsia News</i>, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p><p><p>Full stories can be accessed by clicking on the story title (subscription required). </p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/13/otsuka-looks-to-new-products-as-abilify-plunge-bites" target="_new">Otsuka Looks To New Products As Abilify Plunge Bites</a></p><p>Otsuka has added some flesh to the bones of its strategy to fill the hole left by plunging sales of mainstay product Abilify due to generic competition, with new formulations of the atypical antipsychotic and pipeline CNS drugs seen as driving growth over the next few years.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/13/hengrui-looks-abroad-for-strategic-inlicensing-deal" target="_new">Hengrui Looks Abroad For Strategic In-Licensing Deal</a></p><p>Jiangsu Hengrui has tested new waters to in-license its first drug candidate from overseas under an exclusive licensing agreement with Tesaro, marking its ambition to increase international collaborations under its development strategy for this year. Some analysts predict the deal may be just the start of a broader relationship.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/12/lsk-inks-btk-inhibitor-deal-amid-growing-oncology-interest" target="_new">LSK Inks BTK Inhibitor Deal Amid Growing Oncology Interest</a></p><p>Following Hanmi's major collaboration with Lilly earlier this year, another South Korean firm has reached a licensing agreement on a Bruton's tyrosine kinase (BTK) inhibitor amid growing interest in oncology. Under the agreement, LSK BioPharma acquires global rights in all indications to an oral small molecule irreversible BTK inhibitor from a US university.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/12/otc-and-tcm-businesses-help-bayer-escape-china-slowdown" target="_new">OTC And TCM Businesses Help Bayer Escape China Slowdown</a></p><p>Allergy remedies, contraceptive pills and skin care lotion have helped Bayer to continue its growth momentum in China despite an overall slowdown. With the help of integrating strong brands from local maker Dihon and global firm Merck & Co, the German firm sees a smooth ride ahead.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/12/contrave-bound-for-korea-as-orexigen-links-with-local-firm" target="_new">Contrave Bound For Korea As Orexigen Links With Local Firm</a></p><p>After settling a long dispute with its marketing partner for the US market, Orexigen Therapeutics has inked an agreement with Kwang Dong Pharm to distribute its obesity drug in South Korea, where demand is growing amid an increasing number of hypertension, hyperlipidemia and diabetes patients.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/12/sun-profit-dives-on-ranbaxy-integration-costs" target="_new">Sun Profit Dives On Ranbaxy Integration Costs</a></p><p>Sun Pharmaceutical Industries, India&rsquo;s biggest drug maker, has announced a 60% slump in quarterly net profit from a year earlier, hit by one-off charges as it integrates troubled former rival Ranbaxy, acquired from Japanese owners Daiichi Sankyo earlier this year. But the generics giant says the &ldquo;short-term pain&rdquo; will result in long-term gain.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/11/results-roundup-big-pharma-grapples-with-china-slowdown" target="_new">Results Round-Up: Big Pharma Grapples With China Slowdown</a></p><p>If there was one overall signal to come out of multinationals&rsquo; second quarter results, it was that China can no longer be relied upon to be the major driver of growth in emerging markets that it once was, as sales increases are slowing as a result of cost control policies and generic competition. But while several firms&rsquo; growth in this market fell into single digits in the quarter, the longer term prospects are still seen as positive given strong underlying fundamentals.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/11/indian-cancer-care-chain-hcg-plans-ipo-to-fund-expansion" target="_new">Indian Cancer Care Chain HCG Plans IPO To Fund Expansion</a></p><p>India&rsquo;s biggest cancer treatment hospital chain, HealthCare Global Enterprises, has announced plans for an IPO that&rsquo;s expected to raise at least $100m and says it will also expand in Africa to meet vast &ldquo;unmet demand for cancer care.&rdquo;</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/10/china-foreign-rampd-investments-pass-us-but-slowdown-looming" target="_new">China Foreign R&D Investments Pass US But Slowdown Looming?</a></p><p>China is said to have surpassed the US in luring foreign direct investment for R&D, with the pharmaceutical industry leading the way. However, top industry experts including RDPAC managing director Joseph Cho see caveats and the looming impact of an economic slowdown.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/13/turkey-company-roundup-plant-rampd-investments-taxes-and-lawsuits" target="_new">Turkey Company Roundup: Plant, R&D Investments, Taxes And Lawsuits</a></p><p>Onko Kocsel has opened a new plant to manufacture cancer drugs, while Merck Millipore is increasing cooperation to support pharmaceutical R&D and production in Turkey. Meanwhile, local producers of medical devices are complaining about what they call the &ldquo;unfair application&rdquo; of value added tax, and the Court of Appeal rules in favor of Abdi Ibrahim in a law suit against former sales representatives.</p><p><p>www.pharmasianews.com</p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 249

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>&rsquo;s sister publication <i>PharmAsia News</i>, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150814T120003
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150814T120003
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150814T120003
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029507
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{DB39CCA6-EB88-422C-8247-AB4AD01491E2}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359865
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042435Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

3bb79af2-36e1-4a13-bf78-e8feaeea632f
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042435Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
